MPM BioImpact related stories
All articles and analysis
Third Rock closes debut fund on $378mNewly formed venture firm Third Rock Ventures will use its first fund for investments in early stage biotechnology companies.
- Intercell tops up $50m funding round
The Austrian vaccine developer has landed the largest biotechnology financing round for two years with lead investments from MPM Capital and Global Life Science Ventures.
- DVC hires new life sciences partner
DVC Deutsche Venture Capital, the Munich-based venture capital firm, has bolstered its life sciences team with the appointment of Dr Jan zur Hausen as a partner.
- Deal round-up 07/04/03
Sovereign leads Principal Schools buyout; Epigenomics lands E21m third round; Apax backs E10m Corvil Networks round; Granville Baird backs German MBO; Granville Baird backs German MBO
- MPM nets big return on Idenix exit
The US life sciences investor has sold the hepatitis and HIV treatment company to Novartis in a deal that values the business at up to $612m.
- Deal round-up 08/05/03
Trinity backs E11.5m AePONA round; German VCs buy into semiconductor business; Viventures in broadband access investment; DVC backs Epigenomics third round; Nordic firms back Bone Support
- MPM closes $900M Health Fund III
The US-German healthcare investor has closed its third fund on $900m, making it one of the largest funds ever raised in the sector.
- Deal round-up 27/03/02
VC firms back Roche spin out; AMJPE exits RFO